OCUL301

OCUL301 is a preclinical-stage therapeutic candidate developed by Shenzhen Oculgen Biomedical Technology for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and polypoidal choroidal vasculopathy (PCV). It is characterized as a multi-target program, although the specific biological targets and molecular modality have not been publicly disclosed by the developer. The drug is designed to address the complex pathology of retinal vascular diseases, which involve abnormal angiogenesis and vascular leakage. Given the developer's focus on innovative protein drugs and the standard of care for these indications, OCUL301 is likely a biologic intended for ophthalmic administration.